文献速递肝病

评估resmetirom治疗非酒精性脂肪性肝炎的3期MAESTRO临床项目设计

Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.
PubMed 文献 · Aliment Pharmacol Ther · 2023-10-02

MAESTRO临床项目包含四项研究,旨在评估口服肝脏靶向甲状腺激素受体β选择性激动剂resmetirom治疗非酒精性脂肪性肝炎(NASH)的疗效与安全性。MAESTRO-NASH为关键性连续肝活检试验,计划纳入最多2000例活检确诊的高危NASH成人,随机接受安慰剂、80 mg或100 mg resmetirom每日一次口服,于筛选期、第52周和第54个月进行肝活检。项目设计与监管机构共同制定,以支持resmetirom用于NASH治疗的获批。

要点

  • MAESTRO-NASH纳入最多2000例活检确诊的高危NASH成人,随机接受安慰剂、80 mg或100 mg resmetirom每日一次口服。
  • MAESTRO-NAFLD-1为52周安全性试验,纳入约1400例基于无创检测诊断的NAFLD/推定NASH成人,其中约700例进入52周活性治疗扩展研究MAESTRO-NAFLD-OLE。
  • MAESTRO-NASH-OUTCOMES正在纳入700例代偿良好的NASH肝硬化成人,评估resmetirom延缓进展至肝功能失代偿事件的潜力。

核心结论

  • MAESTRO临床项目与监管机构共同设计,旨在支持resmetirom用于NASH治疗的获批。
  • 基于第52周肝活检、血清生物标志物和影像的替代终点,将由MAESTRO-NASH(第54个月)和MAESTRO-NASH-OUTCOMES(至事件时间)的长期临床肝脏相关结局确认。

研究设计与样本

  • MAESTRO-NASH为关键性连续肝活检试验,纳入最多2000例活检确诊的高危NASH成人,随机接受每日一次口服安慰剂、80 mg resmetirom或100 mg resmetirom,于筛选期、第52周和第54个月进行肝活检。
  • MAESTRO-NAFLD-1为52周安全性试验,纳入约1400例基于无创检测诊断的NAFLD/推定NASH成人。
  • MAESTRO-NAFLD-OLE为52周活性治疗扩展研究,纳入来自MAESTRO-NAFLD-1的约700例患者,进一步评估安全性。
  • MAESTRO-NASH-OUTCOMES正在纳入700例代偿良好的NASH肝硬化成人,评估resmetirom延缓进展至肝功能失代偿事件的潜力。
  • 整个项目纵向评估无创检测(生物标志物、影像)以及经验证的患者报告结局。

主要发现

  • 在NASH成人(NCT02912260)的2期试验中,与安慰剂相比,resmetirom显著减少肝脏脂肪(通过影像)并使相当数量患者的NASH消退且纤维化未恶化(通过肝活检)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD) associated with steatosis, hepatocellular injury, inflammation and fibrosis. In a Phase 2 trial in adults with NASH (NCT02912260), resmetirom, an orally administered, liver-targeted thyroid hormone receptor-β selective agonist, significantly reduced hepatic fat (via imaging) and resolved NASH without worsening fibrosis (via liver biopsy) in a significant number of patients compared with placebo. AIMS: To present the design of the Phase 3 MAESTRO clinical programme evaluating resmetirom for treatment of NASH (MAESTRO-NAFLD-1 [NCT04197479], MAESTRO-NAFLD-OLE [NCT04951219], MAESTRO-NASH [NCT03900429], MAESTRO-NASH-OUTCOMES [NCT05500222]). METHODS: MAESTRO-NASH is a pivotal serial biopsy trial in up to 2000 adults with biopsy-confirmed at-risk NASH. Patients are randomised to a once-daily oral placebo, 80 mg resmetirom, or 100 mg resmetirom. Liver biopsies are conducted at screening, week 52 and month 54. MAESTRO-NAFLD-1 is a 52-week safety trial in ~1400 adults with NAFLD/presumed NASH (based on non-invasive testing); ~700 patients from MAESTRO-NAFLD-1 are enrolled in MAESTRO-NAFLD-OLE, a 52-week active treatment extension to further evaluate safety. MAESTRO-NASH-OUTCOMES is enrolling 700 adults with well-compensated NASH cirrhosis to evaluate the potential for resmetirom to slow progression to hepatic decompensation events. Non-invasive tests (biomarkers, imaging) are assessed longitudinally throughout, in addition to validated patient-reported outcomes. CONCLUSION: The MAESTRO clinical programme was designed in conjunction with regulatory authorities to support approval of resmetirom for treatment of NASH. The surrogate endpoints, based on week 52 liver biopsy, serum biomarkers and imaging, are confirmed by long-term clinical liver-related outcomes in MAESTRO-NASH (month 54) and MAESTRO-NASH-OUTCOMES (time to event).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Harrison SA, Ratziu V, Anstee QM, et al. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2023. PMID: 37786277. doi:10.1111/apt.17734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。